Average daily risk range as a measure for clinical research and routine care

Journal of Diabetes Science and Technology

Volumn 7, Issue 5, 2013, Pages 1370-1375

  Patton, Susana R ^a   Clements, Mark A ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Average daily risk range; Continuous glucose monitoring; Glycemic variability; Measurement; Self monitoring of blood glucose

Indexed keywords

ADRENALIN; C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL;

AGE; AVERAGE DAILY RISK RANGE; BLOOD GLUCOSE MONITORING; CLINICAL PRACTICE; CLINICAL RESEARCH; CONTINUOUS GLUCOSE MONITORING; DIABETES EDUCATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; LABILITY INDEX SCORE; MORTALITY; PATIENT COUNSELING; PREDICTOR VARIABLE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; TELEMEDICINE; TREATMENT OUTCOME; BLOOD; DIABETES MELLITUS; RISK;

BLOOD GLUCOSE; DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; RISK;

EID: 84893638865     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681300700529     Document Type: Review

References (30)

1. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Laffel L, Deeb L, Grey M, Anderson B, Holzmeister LA, Clark N; American Diabetes Association. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care. 2005;28(1):186-212. (Pubitemid 40095803)
2. Risso A, Mercuri F, Quagliaro L, Damante G, Ceriello A. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab. 2001;281(5):E924-30.
3. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes. 2003;52(11):2795-804. (Pubitemid 37339710)
4. Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, Zuodar G, Ceriello A. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis. 2005;183(2):259-67. (Pubitemid 41579276)
5. Giannini S, Benvenuti S, Luciani P, Manuelli C, Cellai I, Deledda C, Pezzatini A, Vannelli GB, Maneschi E, Rotella CM, Serio M, Peri A. Intermittent high glucose concentrations reduce neuronal precursor survival by altering the IGF system: the involvement of the neuroprotective factor DHCR24 (Seladin-1). J Endocrinol. 2008;198(3):523-32.
6. Hou ZQ, Li HL, Gao L, Pan L, Zhao JJ, Li GW. Involvement of chronic stresses in rat islet and INS-1 cell glucotoxicity induced by intermittent high glucose. Mol Cell Endocrinol. 2008;291(1-2):71-8.
7. Ge QM, Dong Y, Zhang HM, Su Q. Effects of intermittent high glucose on oxidative stress in endothelial cells. Acta Diabetol. 2010;47 Suppl 1:97-103.
8. Sun J, Xu Y, Dai Z, Sun Y. Intermittent high glucose enhances proliferation of vascular smooth muscle cells by upregulating osteopontin. Mol Cell Endocrinol. 2009;313(1-2):64-9.
9. Li-Bo Y, Wen-Bo Q, Xiao-Hong L, You-Lun F, Tie Z. Intermittent high glucose promotes expression of proinflammatory cytokines in monocytes. Inflamm Res. 2011;60(4):367-70.
10. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-7.
11. Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, Marra G, Tonutti L, Taboga C, Motz E. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care. 2002;25(8):1439-43. (Pubitemid 41071158)
12. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;57(5):1349-54.
13. Sartore G, Chilelli NC, Burlina S, Lapolla A. Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol. 2013;50(3):437-42.
14. Rodbard D. The challenges of measuring glycemic variability. J Diabetes Sci Technol. 2012;6(3):712-5.
15. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther. 2009;11 Suppl 1:S55-67.
16. Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care. 2006;29(11):2433-8. (Pubitemid 44912248)
17. Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther. 2009;11(9):551-65.
18. Patton SR, Midyett LK, Dolan LM, Powers SW. A comparison of average daily risk range scores for young children with type 1 diabetes mellitus using continuous glucose monitoring and self-monitoring data. Diabetes Technol Ther. 2012;14(3):239-43.
19. Kohnert KD, Vogt L, Augstein P, Heinke P, Zander E, Peterson K, Freyse EJ, Salzsieder E. Relationships between glucose variability and conventional measures of glycemic control in continuously monitored patients with type 2 diabetes. Horm Metab Res. 2009;41(2):137-41.
20. Farhy LS, Ortiz EA, Kovatchev BP, Mora AG, Wolf SE, Wade CE. Average daily risk range as a measure of glycemic risk is associated with mortality in the intensive care unit: a retrospective study in a burn intensive care unit. J Diabetes Sci Technol. 2011;5(5):1087-98.
21. Lipska KJ, Venkitachalam L, Gosch K, Kovatchev B, Van den Berghe G, Meyfroidt G, Jones PG, Inzucchi SE, Spertus JA, DeVries JH, Kosiborod M. Glucose variability and mortality in patients hospitalized with acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012;5(4):550-7.
22. Rodbard D, Bailey T, Jovanovic L, Zisser H, Kaplan R, Garg SK. Improved quality of glycemic control and reduced glycemic variability with use of continuous glucose monitoring. Diabetes Technol Ther. 2009;11(11):717-23.
23. Peña NV, Torres M, Cardona JA, Iniesta R. Impact of telemedicine assessment on glycemic variability in children with type 1 diabetes mellitus. Diabetes Technol Ther. 2013;15(2):136-42.
24. Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther. 2011;13(9):921-8.
25. Younge T, Monaghan M, McCarter R, Cogen F, Streisand R. Use of average daily risk range (ADRR) in children with type 1 diabetes (T1D). Presented at the Pediatric Acedemic Society Meeting, Boston, MA, April 28, 2012.
26. Pitsillides AN, Anderson SM, Kovatchev B. Hypoglycemia risk and glucose variability indices derived from routine self-monitoring of blood glucose are related to laboratory measures of insulin sensitivity and epinephrine counterregulation. Diabetes Technol Ther. 2011;13(1):11-7.
27. Kim SK, Kwon SB, Yoon KH, Ahn KJ, Kang JG, Jung HS, Kang ES, Kim JH, Kim KW. Assessment of glycemic lability and severity of hypoglycemia in Korean patients with type 1 diabetes. Endocr J. 2011;58(6):433-40.
28. Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A. In type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabet Med. 2008;25(3):326-32. (Pubitemid 351322703)
29. .McCall AL, Cox DJ, Brodows R, Crean J, Johns D, Kovatchev B. Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine. Diabetes Technol Ther. 2009;11(6):339-44.
30. .Rodbard D, Jovanovic L, Garg SK. Responses to continuous glucose monitoring in subjects with type 1 diabetes using continuous subcutaneous insulin infusion or multiple daily injections. Diabetes Technol Ther. 2009;11(12):757-65.